G von Minckwitz
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. Ann Oncol 2022; 33:743-744.
18.05.2022Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
18.05.2022Ann Oncol 2022; 33:743-744
Loibl S, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober Jens, Sinn B V, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30:1279-1288.
01.01.2019A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
01.01.2019Ann Oncol 2019; 30:1279-1288
Loibl S, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober Jens, Sinn B V, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Möbus V, Kurbacher C, Untch M, Konecny G, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H, Jackisch C, AGO Breast Study Group (AGO-B). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29:178-185.
01.01.2018Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
01.01.2018Ann Oncol 2018; 29:178-185
Möbus V, Kurbacher C, Untch M, Konecny G E, Hinke A, Runnebaum I B, von Minckwitz G, Harbeck N, Huober Jens, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H J, Jackisch C, AGO Breast Study Group (AGO-B)
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
Villegas S, Denkert C, Mehta K, Müller V, Kümmel S, Engels K, Lederer B, Pfitzner B, Schem C, Furlanetto J, Marmé F, Weber K, Huober J, von Minckwitz G, Darb-Esfahani S, Loibl S. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2017; 168:179-187.
25.11.2017Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
25.11.2017Breast Cancer Res Treat 2017; 168:179-187
Villegas S L, Denkert C, Mehta K, Müller V, Kümmel S, Engels K, Lederer B, Pfitzner B M, Schem C, Furlanetto J, Marmé F, Weber K, Huober Jens, von Minckwitz G, Darb-Esfahani S, Loibl S
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober J, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 2017; 28:1803-1810.
01.08.2017German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
01.08.2017Ann Oncol 2017; 28:1803-1810
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober Jens, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H-J, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsky P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer 2016; 64:12-21.
17.06.2016Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
17.06.2016Eur J Cancer 2016; 64:12-21
von Minckwitz G, Jackisch C, Kümmel S, Fasching P A, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober Jens, Gerber B, Zahm D M, Hilfrich J, Costa S D, Dubsky P, Blohmer J U, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75:556-565.
17.06.2015Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
17.06.2015Geburtshilfe Frauenheilkd 2015; 75:556-565
Untch M, Blohmer J-U, Costa S-D, Decker T, Diel I, Fasching P A, Fehm T, Janni W, Lück H-J, Maass N, Scharl A, Beckmann M W, Jackisch C, Thomssen C, Harbeck N, Huober Jens, von Minckwitz G, Gerber B, Kreipe H-H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
Lindner J, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober J, Sinn B, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner B, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol 2014; 26:95-100.
29.10.2014Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
29.10.2014Ann Oncol 2014; 26:95-100
Lindner J L, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober Jens, Sinn B V, Loibl S, Denkert C, Ataseven B, Fasching P A, Pfitzner B M, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
Deuker J, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C, Meinerz W, Grasshoff S, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372.
15.09.2014Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
15.09.2014Ann Oncol 2014; 25:2363-2372
Deuker J-U, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D-M, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H-U, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C-H, Meinerz W, Grasshoff S-T, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C-C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J-U, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J U, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
von Minckwitz G, Costa S, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J, Hanusch C, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Ann Oncol 2013; 25:81-9.
21.11.2013Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
21.11.2013Ann Oncol 2013; 25:81-9
von Minckwitz G, Costa S D, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J U, Hanusch C, Rezai M, Fasching P A, Huober Jens, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Gerber B, Jackisch C, Kunz G, Blohmer J, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.
17.10.2013Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
17.10.2013Ann Oncol 2013; 24:2978-84
Gerber B, Jackisch C, Kunz G, Blohmer J U, Huober Jens, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J, Budczies J, Mehta K, Fehm T, Huober J, Loibl S, Müller B, Eidtmann H, Schmitt W, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24:2786-93.
22.08.2013Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
22.08.2013Ann Oncol 2013; 24:2786-93
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J U, Budczies J, Mehta K M, Fehm T, Huober Jens, Loibl S, Müller B M, Eidtmann H, Schmitt W D, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
Witzel I, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Schem C, Mau C, Fasching P, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Müller V. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer 2012; 107:956-60.
14.08.2012Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
14.08.2012Br J Cancer 2012; 107:956-60
Witzel I, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober Jens, Zu Eulenburg C, Issa-Nummer Y, Untch M, Schem C, Mau C, Fasching P A, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Müller V
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
von Minckwitz G, Kaufmann M, Mehta K, Loibl S, Skacel T, Vescia S, Grasshoff S, Jackisch C, Costa S, Huober J, Hilfrich J, Gerber B, Eidtmann H, Eiermann W, du Bois A, Kümmel S, German Breast Group. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:292-8.
01.02.2008Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
01.02.2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:292-8
von Minckwitz G, Kaufmann M, Mehta K M, Loibl S, Skacel T, Vescia S, Grasshoff S-T, Jackisch C, Costa S D, Huober Jens, Hilfrich J, Gerber B, Eidtmann H, Eiermann W, du Bois A, Kümmel S, German Breast Group